Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
3/27/2026, 12:00:00 AM
Received drug registration approval from China's NMPA on 2026-03-27 for the third indication of Xinyue®; Medium importance estimated as new indications drive growth expected.
Korean Translation
2026-03-27에 중국 국가약품감독관리국(NMPA)으로부터 신위에®의 세 번째 적응증 허가를 취득함. 신규 적응증 추가에 따른 시장 확대가 예상되어 중간 수준의 중요도로 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Earnings Release
Q1 2026 earnings release for April 29, 2026 scheduled. Minimal market impact from the date announcement expected.
4/29/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
An investor relations (IR) meeting to announce the group's integrated strategy and the progress of major pipelines; low impact anticipated as it is a routine communication event, scheduled.
4/9/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Cancellation of 9.11 million treasury shares, valued at approximately KRW 1.71 trillion, effective April 1, 2026. This largest-ever cancellation is expected to have a high market impact.
4/1/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
The 82nd Annual General Meeting of Shareholders on 2026-03-30 is a routine meeting with low expected price impact scheduled.
3/30/2026, 12:00:00 AM
Hanwha Corp (000880) · Other
The ex-dividend date for the 2025 final dividend of 1,100 KRW per common share is scheduled for 2026-03-30; market impact is estimated to be low (>=1%) following typical dividend adjustments, scheduled.
3/30/2026, 12:00:00 AM